Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: Bacterial Vaginosis, Herpes Simplex Virus Type II
In brief
We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2. We have preliminary data that suggests the presence of HSV-2 increases the risk for Group B Streptococcus colonization as well as many other deleterious organisms (e.g. Streptococcus pseudoporcinus), in addition to increasing the risk for acquisition of BV-associated vaginal flora. We will be examining the effects of suppressive therapy on the vaginal flora of any HSV-2 seropositive woman.
Key facts
- Study ID
- NCT00682721
- Run by
- University of Pittsburgh
- People needed
- 0
- Starts
- 2009-02-01
- Expected to finish
- 2010-09-01
- Last updated by the study team
- 2012-03-02
Who can join
Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Magee-Womens Hospital of UPMC — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.